Andrew O. Wahl, MD

Articles

ACR Appropriateness Criteria® Adjuvant Management of Early-Stage Endometrial Cancer

Andrew O. Wahl, MD;David K. Gaffney, MD, PhD;Anuja Jhingran, MD;Catheryn M. Yashar, MD;Matthew Biagioli, MD;Mohamed A. Elshaikh, MD;Shruti Jolly, MD;Elizabeth Kidd, MD;Larissa J. Lee, MD;Linna Li, MD;David H. Moore, MD;Gautam G. Rao, MD;Ned L. Williams, DO;William Small, Jr, MD

September 15th 2016

After a review of the published literature, the panel voted on three variants to establish best practices for the utilization of imaging, radiotherapy, and chemotherapy after primary surgery for early-stage endometrial cancer.

ACR Appropriateness Criteria® Adjuvant Therapy in Vulvar Cancer

Shruti Jolly, MD;Payal Soni, MD;David K. Gaffney, MD, PhD;Matthew Biagioli, MD;Mohamed A. Elshaikh, MD;Anuja Jhingran, MD;Elizabeth Kidd, MD;Larissa J. Lee, MD;Linna Li, MD;David H. Moore, MD;Gautam G. Rao, MD;Andrew O. Wahl, MD;Ned L. Williams, DO;Catheryn M. Yashar, MD;William Small, Jr, MD

November 16th 2015

The panel reviewed the pertinent literature in vulvar cancer and voted on three variants to establish appropriate use of imaging, adjuvant radiation, including dose, fields, and technique, as well as adjuvant chemotherapy. This report will aid clinicians in selecting appropriate patients for adjuvant treatment and will provide guidelines for the optimal delivery of adjuvant radiation therapy and chemotherapy.

ACR Appropriateness Criteria® Management of Vaginal Cancer

Larissa J. Lee, MD;Anuja Jhingran, MD;Elizabeth Kidd, MD;Higinia Rosa Cardenes, MD, PhD;Mohamed A. Elshaikh, MD;Beth Erickson, MD;Nina A. Mayr, MD;David Moore, MD;Ajmel A. Puthawala, MD;Gautam G. Rao, MD;William Small, Jr, MD;Mahesh A. Varia, MD;Andrew O. Wahl, MD;Aaron H. Wolfson, MD;Catheryn M. Yashar, MD;William Yuh, MD;David K. Gaffney, MD, PhD

November 15th 2013

This article represents the consensus opinion of an expert panel and may be used to inform clinical recommendations in vaginal cancer management.

Inoperable Pancreatic Cancer: Standard of Care

Kari B. Wisinski, MD;Andrew O. Wahl, MD;William Small, Jr, MD;Al B. Benson III, MD, FACP

November 16th 2007

Inoperable pancreatic adenocarcinoma is a dilemma that oncologists frequently encounter. Only 15% to 20% of patients are diagnosed when cancer of the pancreas is still surgically resectable. However, pancreaticoduodenectomy is the only curative option for this disease and should be offered to all patients who meet resection criteria and do not have significant comorbidities. For inoperable pancreatic cancer, the goals of treatment are to palliate symptoms and prolong life. Improved survival in locally advanced disease has been demonstrated with chemoradiation plus fluorouracil or with gemcitabine (Gemzar) alone. In metastatic disease, single-agent gemcitabine has been associated with improvement in symptoms and survival. Trials combining various chemotherapeutic agents with gemcitabine have not had a significant impact on overall survival, although meta-analyses suggest a small benefit. The targeted agent erlotinib (Tarceva) has shown a modest improvement in overall survival in combination with gemcitabine. This combination is another option for first-line therapy in patients with locally advanced or metastatic disease. Despite these recent advances, survival for patients with inoperable pancreatic cancer continues to be poor. Future investigations need to focus on understanding the molecular nature of this malignancy, with the goal of developing interventions based on this knowledge.